Navigation Links
VIA Pharmaceuticals to Present at Fourth Annual Noble Financial Equity Conference
Date:8/12/2008

SAN FRANCISCO, Aug. 12 /PRNewswire-FirstCall/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, announced today that James G. Stewart, senior vice president and chief financial officer of VIA, will present a company update at the Fourth Annual Noble Financial Equity Conference at 8:00 a.m. PT on Tuesday, August 19, 2008 at the Loews Lake Las Vegas Resort in Nevada.

Interested parties may access a live webcast including a virtual slide presentation from the investor section of the VIA website, http://www.viapharmaceuticals.com. A replay will be archived on the VIA website for at least one week following the presentation.

About VIA Pharmaceuticals, Inc.

VIA Pharmaceuticals, Inc. is a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease. VIA is building a pipeline of small-molecule drugs that target a significant unmet medical need: reducing inflammation in the blood vessel wall, which is an underlying cause of atherosclerosis and its complications, including heart attack and stroke. The company's lead drug candidate, VIA-2291, is in multiple Phase 2 clinical studies in patients with cardiovascular disease. For more information, visit: http://www.viapharmaceuticals.com.

About Noble Financial

Noble Financial is a privately-held, full-service capital markets firm driven by what is often overlooked by other firms -- uncovering the value embedded in the orphaned, undiscovered or misunderstood company. The company focuses on converting market inefficiencies into profit opportunities. Noble Financial supports emerging companies through strategic advice, investment banking, market-making, sales & trading, comprehensive equity research, and the development of institutional support. Noble Financial's equity conferences -- 2008 marks their fourth annual -- allow for a unique blend of professional and personal interaction among a diverse cross-section of executives. The company has operated for 24 years and has offices in Florida, New York City and Boston.


'/>"/>
SOURCE VIA Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/25/2017)... ... 2017 , ... Having met specific requirements for its quality ... to provide product development services that consistently meet customer and applicable ... have a lot at stake when they invest in developing medical products ...
(Date:9/22/2017)... , ... September 22, 2017 , ... ... recently raised nearly $200,000 via Kickstarter. The proceeds will be used to fund ... the B2v2, exceeding the original Kickstarter goal by nearly 1,000%. , The B2v2 ...
(Date:9/22/2017)... ... 2017 , ... Precision Periodontics and Implant Dentistry's Dr. Michael ... treatments. Drs. Hoge and Zalewsky are members of an elite class of dental ... option that produces real results. , "Like many of my colleagues, I was ...
(Date:9/22/2017)... ... September 22, 2017 , ... The effectiveness ... being assessed in clinical trials in the United States. (clinicaltrials.gov : NCT02973893) , ... or physician or find your nearest participating clinic here https://factor-therapeutics.com/clinical-trials/ and ...
Breaking Biology Technology:
(Date:5/16/2017)...  Veratad Technologies, LLC ( www.veratad.com ), an innovative ... verification solutions, announced today they will participate as a ... thru May 17, 2017, in Washington D.C.,s ... Identity impacts the lives of billions ... evolving digital world, defining identity is critical to nearly ...
(Date:4/24/2017)... April 24, 2017 Janice Kephart ... with  Identity Strategy Partners, LLP (IdSP) , today ... without President Trump,s March 6, 2017 Executive ... , refugee vetting can be instilled with greater confidence, ... now, all refugee applications are suspended by until ...
(Date:4/17/2017)... 17, 2017 NXT-ID, Inc. (NASDAQ: NXTD ... filing of its 2016 Annual Report on Form 10-K on Thursday ... ... available in the Investor Relations section of the Company,s website at ... website at http://www.sec.gov . 2016 Year Highlights: ...
Breaking Biology News(10 mins):